Pallas Capital Advisors LLC Purchases New Stake in Myriad Genetics, Inc. $MYGN

Pallas Capital Advisors LLC bought a new position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 10,808 shares of the company’s stock, valued at approximately $57,000.

Several other institutional investors have also modified their holdings of the business. Jennison Associates LLC lifted its holdings in shares of Myriad Genetics by 3.0% during the 1st quarter. Jennison Associates LLC now owns 60,811 shares of the company’s stock valued at $539,000 after purchasing an additional 1,796 shares in the last quarter. Natixis Advisors LLC raised its position in Myriad Genetics by 1.3% in the 1st quarter. Natixis Advisors LLC now owns 212,138 shares of the company’s stock valued at $1,882,000 after buying an additional 2,810 shares during the last quarter. ProShare Advisors LLC raised its position in Myriad Genetics by 12.2% in the 4th quarter. ProShare Advisors LLC now owns 26,982 shares of the company’s stock valued at $370,000 after buying an additional 2,933 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Myriad Genetics by 520.8% during the 1st quarter. GAMMA Investing LLC now owns 4,470 shares of the company’s stock worth $40,000 after purchasing an additional 3,750 shares in the last quarter. Finally, State of Wyoming raised its stake in shares of Myriad Genetics by 147.0% during the 1st quarter. State of Wyoming now owns 8,641 shares of the company’s stock worth $77,000 after purchasing an additional 5,143 shares in the last quarter. Institutional investors own 99.02% of the company’s stock.

Myriad Genetics Trading Down 1.8%

MYGN stock opened at $7.70 on Wednesday. The firm has a market capitalization of $716.45 million, a PE ratio of -1.80 and a beta of 1.92. Myriad Genetics, Inc. has a 1-year low of $3.76 and a 1-year high of $27.55. The business’s 50 day simple moving average is $5.89 and its 200 day simple moving average is $6.31.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.